Overall verdict
Neutral
4.5/10
1-year performance
+14.83%
Score breakdown
Up 14.8% over 1 year, 100% of the 52-week range.
Strongest: Financial strength 6.7/10. Weakest: Profitability 0.0/10.
17 analysts, target -0.0% vs the price.
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.
The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines.
It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases.
The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Sector
Health Care
Industry
Biotechnology
Primary listing
Asx
Australia
CEO
Gordon Naylor
Founded
1916
Employees
29 000
Revenue / employee
552 628 USD
Next earnings
February 10, 2027
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
204.54 AUD
52-week low
90.00 AUD
1-year performance
14.83%
Rising
Year-to-date performance
17.89%
Rising
Drawdown
0.00%
Near its high
Position in the 52-week range
100% of range
Range: 210.95 AUD - 249.88 AUD (comparables only)
The price implies growth of 7.09% per year; the company grows at 10.97%.
Gross margin 47.8%, the company loses 15.6% of its revenue, ROIC -8.9%, ROE -14.3%.
Net margin
-15.65%
Negative
Sector -13.47%|S&P 13.40%
Gross margin
47.82%
Low
Return on equity (ROE)
-14.27%
Negative
Sector -18.81%|S&P 17.06%
Return on invested capital (ROIC)
-8.93%
Negative
Free cash flow margin (FCF)
17.59%
High
Margin stability
11.3 pts
Very uneven
Revenue to net income
Growth
2.7/10Revenue up 5.5% over 1 year, 11.0% a year over 5.
Revenue (trailing 12 months)
16.0Md USD
Revenue growth (1y)
5.50%
Moderate
Revenue growth (3y)
18.29%
Solid
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
-2.62%
Revised down
Valuation
5.6/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 31.0x|S&P 23.6x
Forward P/E
23.1x
Fair
EV / EBITDA
14.9x
Fair
Sector 18.0x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Fair value (reverse DCF)
230.42 AUD
Undervalued
Market cap
66.2Md USD
Financial strength
6.7/10Cash covers 13.9% of the debt, net debt/EBITDA 1.8x.
Net debt / EBITDA
1.8x
Tight
Gearing (net debt / equity)
57.54%
Solid
Cash
1.5Md USD
Cash / market cap
2.28%
Stretched
Cash / total debt
13.89%
Stretched
Interest coverage
9.4x
Solid
Net debt
9.4Md USD
Equity
16.3Md USD
Closed daily candles, 2 years
Last close on November 11, 2026: 201.68 AUD
- MM20197.52
- MM50185.66
- MM200145.38
- RSI 1469.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.56%
200-day average slope, 3 months
+0.80%
50-day average slope, 1 month
+10.43%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.03 % per day
Volatility change
-57.32%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 6.06 (9) | 6.19 (17) | 15 758 (17) | 5 087 (17) | 2 818 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | ONC | 6.6 | 6.6 | 47.2Md USD | 53.2x | 13.9 % | 34.0 % | 14.5 % | -4.4x | 3.1 % | 25.7 % | ||
| 3 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 4 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 5 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 6 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 7 | CSL | 4.5 | 3.7 | 66.2Md USD | Not meaningful (loss) | -15.6 % | 5.5 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
